Synlogic (SYBX) investor relations material

Executive summary

• Discontinued lead clinical trial Synpheny-3 for PKU in February 2024 after internal review indicated it was unlikely to meet its primary endpoint; not due to safety concerns.

• Corporate restructuring reduced workforce to one full-time employee and engaged consultants to support strategic review and operations.

• Current strategy is focused on exploring strategic alternatives, including a potential merger or sale.

• Delisted from Nasdaq in January 2026; now trades on the OTC market as a public shell.

Financial highlights

• Net income for Q1 2026 was $0.7 million, up from $0.3 million in Q1 2025, driven by a $1.9 million gain on warrant remeasurement.

• Revenue was $49,000 for Q1 2026, compared to $22,000 in Q1 2025.

• Operating expenses increased to $1.3 million from $0.9 million year-over-year, mainly due to higher G&A and restructuring costs.

• Cash and cash equivalents at March 31, 2026 were $14.1 million, down from $14.7 million at year-end 2025.

• Accumulated deficit stood at $442.0 million as of March 31, 2026.

Outlook and guidance

• Cash and cash equivalents expected to fund operations at current levels for at least the next 12 months.

• Expenses anticipated to remain stable in the near term as strategic alternatives are pursued.

• No expectation of product revenue generation; future funding needs depend on outcome of strategic review.